比克替拉韦在生殖道和直肠的分布及HIV-1 RNA衰减动力学
这项前瞻性多中心研究纳入23例未治HIV-1成人,启动比克替拉韦/恩曲他滨/丙酚替诺福韦后,精浆和直肠液中HIV-1 RNA快速下降,女性宫颈阴道液第14天均检测不到。第28天和12周时,精浆、直肠组织、宫颈阴道液中总比克替拉韦浓度分别为血浆的2.7%、2.6%、2.8%,游离部分占42.6%–51.1%,均远高于EC50(1.1 ng/mL)。
要点
- 精浆和直肠液中HIV-1 RNA下降速度及检测不到的时间均快于血浆。
- 女性宫颈阴道液HIV-1 RNA第14天全部检测不到。
- 精浆、直肠组织、宫颈阴道液中游离比克替拉韦浓度高度超过EC50。
核心结论
- 比克替拉韦/恩曲他滨/丙酚替诺福韦使生殖道和直肠液中HIV-1 RNA快速衰减。
- 精浆、直肠组织和宫颈阴道液中游离比克替拉韦浓度远高于EC50(1.1 ng/mL)。
研究设计与样本
- 前瞻性多中心研究,纳入15例男性和8例女性未治HIV-1成人,启动比克替拉韦/恩曲他滨/丙酚替诺福韦。
- 在基线、第3、7、14、28天及第12、24周检测血浆、精浆、直肠液和宫颈阴道液HIV-1 RNA(定量下限40 copies/mL)。
- 第28天和第12周用经验证的液相色谱-串联质谱法测定血浆、精浆、宫颈阴道液和直肠组织中总及蛋白未结合比克替拉韦24小时谷浓度。
主要发现
- 精浆、直肠液、宫颈阴道液基线HIV-1 RNA>40 copies/mL者分别为12/15、13/15、4/8,中位数分别为3.54(2.41–3.79)、4.19(2.98–4.70)、2.56(1.61–3.56)log10 copies/mL。
- 精浆初始衰减斜率显著低于直肠液和血浆;精浆和直肠液HIV-1 RNA检测不到的时间显著短于血浆。
- 所有女性第14天宫颈阴道液HIV-1 RNA均检测不到。
- 精浆、直肠组织、宫颈阴道液总比克替拉韦中位数分别为65.5(20.1–923)ng/mL、74.1(6.0–478.5)ng/g、61.6(14.4–1760.2)ng/mL,分别为血浆浓度的2.7%、2.6%、2.8%。
- 精浆、直肠组织、宫颈阴道液蛋白未结合比克替拉韦比例分别为51.1%、44.6%、42.6%。
关键数值与推荐
- 精浆、直肠组织、宫颈阴道液总比克替拉韦浓度分别为血浆的2.7%、2.6%、2.8%。
- 蛋白未结合比克替拉韦在精浆、直肠组织、宫颈阴道液分别为51.1%、44.6%、42.6%。
- 比克替拉韦EC50为1.1 ng/mL,各部位游离浓度均高度超过该值。
临床怎么用
- 支持比克替拉韦/恩曲他滨/丙酚替诺福韦在生殖道和直肠部位快速抑制HIV-1 RNA。
- 精浆和直肠液病毒衰减快于血浆,提示这些部位暴露于有效药物浓度。
局限性
- 样本量小(15例男性、8例女性)。
- 仅评估比克替拉韦/恩曲他滨/丙酚替诺福韦方案,随访至24周。
- 未报告临床结局,仅报告病毒学和药代动力学指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The pharmacokinetics of bictegravir (BIC) and its association with the decay of human immunodeficiency virus (HIV)-1 RNA in genital fluids and the rectum have not yet been addressed. METHODS: We conducted a prospective, multicenter study of antiretroviral-naive people living with HIV-1 and initiating BIC/emtricitabine (FTC)/tenofovir alafenamide (TAF). HIV-1 RNA was measured (limit of quantification, 40 copies/mL) in blood plasma (BP), seminal plasma (SP), rectal fluid (RF), and cervicovaginal fluid (CVF) at baseline; Days 3, 7, 14, and 28; and Weeks 12 and 24. Total and protein-unbound BIC concentrations at 24 hours postdose (C24h) were quantified in BP, SP, CVF and rectal tissue (RT) on Day 28 and Week 12 using a validated liquid chromatography-tandem mass spectrometry assay. RESULTS: The study population comprised 15 males and 8 females. In SP, RF, and CVF, the baseline HIV-1 RNA was >40 copies/mL in 12/15, 13/15, and 4/8 individuals, respectively, with medians of 3.54 (2.41-3.79), 4.19 (2.98-4.70), and 2.56 (1.61-3.56) log10 copies/mL, respectively. The initial decay slope was significantly lower in SP than in RF and BP. The time to undetectable HIV-1 RNA was significantly shorter in SP and RF than in BP. All women achieved undetectable HIV-1 RNA in CVF at Day 14. The median total BIC concentrations in SP, RT, and CVF were 65.5 (20.1-923) ng/mL, 74.1 (6.0-478.5) ng/g, and 61.6 (14.4-1760.2) ng/mL, respectively, representing 2.7%, 2.6%, and 2.8% of the BP concentration, respectively, while the protein-unbound fractions were 51.1%, 44.6%, and 42.6%, respectively. CONCLUSIONS: BIC/FTC/TAF led to rapid decay of HIV-1 RNA in genital and rectal fluids. Protein-unbound BIC concentrations in SP, RT, and CVF highly exceeded the half-maximal effective concentration (EC50) value (1.1 ng/mL). CLINICAL TRIALS REGISTRATION: EudraCT 2018-002310-12.
引用
- Imaz A, Tiraboschi JM, Niubó J, et al. Dynamics of the Decay of Human Immunodeficiency Virus (HIV) RNA and Distribution of Bictegravir in the Genital Tract and Rectum in Antiretroviral-naive Adults Living With HIV-1 Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58). Clin Infect Dis. 2021. PMID: 32945851. doi:10.1093/cid/ciaa1416
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。